Clinical Significance Unveiled: Understanding the Meaning of FACE-Q Skin Cancer Scores for Improved Patient Care.

IF 3.3 2区医学 Q2 ONCOLOGY

Psycho‐Oncology Pub Date : 2024-10-01 DOI:10.1002/pon.70009

Inge J Veldhuizen, Stephen W Dusza, Alyce Kuo, Abdullah Aleisa, Elliot Blue, Sushmita Adhikari, Umer Nadir, Kim Le, Soroush Kazemi, Adam V Sutton, Rajiv I Nijhawan, Daniel B Eisen, Anthony M Rossi, Divya Srivastava, Ashley Wysong, Kishwer S Nehal, Anne F Klassen, Erica H Lee

{"title":"Clinical Significance Unveiled: Understanding the Meaning of FACE-Q Skin Cancer Scores for Improved Patient Care.","authors":"Inge J Veldhuizen, Stephen W Dusza, Alyce Kuo, Abdullah Aleisa, Elliot Blue, Sushmita Adhikari, Umer Nadir, Kim Le, Soroush Kazemi, Adam V Sutton, Rajiv I Nijhawan, Daniel B Eisen, Anthony M Rossi, Divya Srivastava, Ashley Wysong, Kishwer S Nehal, Anne F Klassen, Erica H Lee","doi":"10.1002/pon.70009","DOIUrl":null,"url":null,"abstract":"Objective: The FACE-Q Skin Cancer Module is a Patient-Reported Outcome Measure (PROM) utilized to assess outcomes following facial skin cancer resection. However, the lack of Minimal Important Difference (MID) estimates hinders the interpretability of the PROM scores. This study established MID estimates for the four outcome scales from the FACE-Q Skin Cancer Module using distribution-based methods.Methods: A prospective cohort study at four hospitals in the United States, enrolled participants who underwent Mohs Micrographic Surgery (MMS) for facial skin cancer between April 2020 and April 2022. Participants completed the Satisfaction with Facial Appearance, Appearance-related Psychosocial Distress, Cancer Worry, and Appraisal of Scars scales at four time points: pre-operatively, 2-week, 6-month, and 1-year post-surgery.Results: A total of 990 patients participated in the study, with completion rates of 98.4% for the pre-operative assessment, 70.8% at 2 weeks, 59.3% at 6 months, and 60.4% at 1 year. MID estimates, calculated using 0.2 standard deviation and 0.2 standardized response mean, were determined for the four scales. The mean MID estimates, based on a Rasch transformed score ranging from 0 to 100, were 5 for the Appraisal of Scars scale and 4 for the remaining three scales.Conclusion: This multicenter study provides valuable MID estimates for the FACE-Q Skin Cancer Module, specifically for the MMS patient population, enabling clinicians and researchers to better interpret scores, determine appropriate sample sizes, and apply the findings in clinical care.","PeriodicalId":20779,"journal":{"name":"Psycho‐Oncology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psycho‐Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pon.70009","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The FACE-Q Skin Cancer Module is a Patient-Reported Outcome Measure (PROM) utilized to assess outcomes following facial skin cancer resection. However, the lack of Minimal Important Difference (MID) estimates hinders the interpretability of the PROM scores. This study established MID estimates for the four outcome scales from the FACE-Q Skin Cancer Module using distribution-based methods.

Methods: A prospective cohort study at four hospitals in the United States, enrolled participants who underwent Mohs Micrographic Surgery (MMS) for facial skin cancer between April 2020 and April 2022. Participants completed the Satisfaction with Facial Appearance, Appearance-related Psychosocial Distress, Cancer Worry, and Appraisal of Scars scales at four time points: pre-operatively, 2-week, 6-month, and 1-year post-surgery.

Results: A total of 990 patients participated in the study, with completion rates of 98.4% for the pre-operative assessment, 70.8% at 2 weeks, 59.3% at 6 months, and 60.4% at 1 year. MID estimates, calculated using 0.2 standard deviation and 0.2 standardized response mean, were determined for the four scales. The mean MID estimates, based on a Rasch transformed score ranging from 0 to 100, were 5 for the Appraisal of Scars scale and 4 for the remaining three scales.

Conclusion: This multicenter study provides valuable MID estimates for the FACE-Q Skin Cancer Module, specifically for the MMS patient population, enabling clinicians and researchers to better interpret scores, determine appropriate sample sizes, and apply the findings in clinical care.

查看原文本刊更多论文

揭开临床意义的面纱：了解 FACE-Q 皮肤癌评分的意义，改善患者护理。

目的：FACE-Q 皮肤癌模块是一种患者报告结果测量（PROM），用于评估面部皮肤癌切除术后的结果。然而，由于缺乏最小重要差异（MID）估计值，PROM评分的可解释性受到影响。本研究采用基于分布的方法确定了 FACE-Q 皮肤癌模块中四个结果量表的 MID 估计值：在美国四家医院进行的一项前瞻性队列研究招募了 2020 年 4 月至 2022 年 4 月间因面部皮肤癌接受莫氏显微手术 (MMS) 的参与者。参与者在四个时间点（术前、术后2周、术后6个月和术后1年）完成了面部外观满意度、外观相关心理社会压力、癌症担忧和疤痕评价量表：共有 990 名患者参与了这项研究，术前评估完成率为 98.4%，2 周评估完成率为 70.8%，6 个月评估完成率为 59.3%，1 年评估完成率为 60.4%。使用 0.2 标准差和 0.2 标准化反应平均值计算出了四个量表的 MID 估计值。根据从 0 到 100 的 Rasch 转换得分，疤痕评估量表的平均 MID 估计值为 5，其余三个量表的平均 MID 估计值为 4：这项多中心研究为FACE-Q皮肤癌模块提供了有价值的MID估计值，特别是针对MMS患者群体，使临床医生和研究人员能够更好地解释评分、确定适当的样本大小，并将研究结果应用于临床护理中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psycho‐Oncology 医学-心理学

CiteScore

6.30

自引率

8.30%

发文量

220

审稿时长

3-8 weeks

期刊介绍： Psycho-Oncology is concerned with the psychological, social, behavioral, and ethical aspects of cancer. This subspeciality addresses the two major psychological dimensions of cancer: the psychological responses of patients to cancer at all stages of the disease, and that of their families and caretakers; and the psychological, behavioral and social factors that may influence the disease process. Psycho-oncology is an area of multi-disciplinary interest and has boundaries with the major specialities in oncology: the clinical disciplines (surgery, medicine, pediatrics, radiotherapy), epidemiology, immunology, endocrinology, biology, pathology, bioethics, palliative care, rehabilitation medicine, clinical trials research and decision making, as well as psychiatry and psychology. This international journal is published twelve times a year and will consider contributions to research of clinical and theoretical interest. Topics covered are wide-ranging and relate to the psychosocial aspects of cancer and AIDS-related tumors, including: epidemiology, quality of life, palliative and supportive care, psychiatry, psychology, sociology, social work, nursing and educational issues. Special reviews are offered from time to time. There is a section reviewing recently published books. A society news section is available for the dissemination of information relating to meetings, conferences and other society-related topics. Summary proceedings of important national and international symposia falling within the aims of the journal are presented.